Vmbook Online ordering

Icons

I'm happy to help you with your inquiry about Icon plc (ICLR), a public company that is listed on the NASDAQ stock exchange in the USA. However, I believe there may be a misunderstanding in your question regarding the term "repeat" as it pertains to a public company and its stock. If you meant to ask about Icon's financial performance, earnings, and growth, I would be happy to provide some general information on those topics.

Icon plc is a global provider of drug development solutions and services, based in Dublin, Ireland. The company operates in three main segments: Drug Development Services, Healthcare Services, and Global Site Network. Icon has a strong track record of financial performance, and its stock has performed well over the past five years.

In terms of earnings, Icon has reported consistent growth in recent years. In its most recent financial report for the year ended December 31, 2021, the company reported revenue of $3.9 billion, representing an increase of 14% compared to the previous year. Icon's net income for the year was $310.9 million, up from $253.5 million in 2020.

Icon has also demonstrated strong growth in its earnings per share (EPS) over the past five years, with a compound annual growth rate (CAGR) of 24.5% from 2017 to 2021. The company's EPS for the full year 2021 was $5.25, up from $4.16 in 2020.

In addition to its strong financial performance, Icon has a solid track record of delivering innovative drug development solutions for its clients. The company's Global Site Network provides access to a large and diverse patient population, which enables it to conduct clinical trials more efficiently and effectively.

Overall, Icon plc is a well-established and financially stable public company with a strong track record of earnings growth and innovation in the drug development industry.